Research
Epitranscriptomics & Cancer Adaptation : A.David

Activities

Our research work focuses on the contribution of post-transcriptional mechanisms on cancer cell adaptation, in particular RNA epigenetic & translational control.

More..

Zotero public









Cancel


11 Items
Title  Creator  Group name  Publishing year 
First-line real-world treatment patterns and survival outcomes in women younger or older than 40 years with metastatic breast cancer in the real-life multicenter French ESME cohort Galvin et al. EquipeCTCS 2024-01
Real-world clinical and survival outcomes of patients with early relapsed triple-negative breast cancer from the ESME national cohort Grinda et al. EquipeCTCS 2023-08
Association between progression-free survival and overall survival in women receiving first-line treatment for metastatic breast cancer: evidence from the ESME real-world database Courtinard et al. EquipeCTCS 2023-03-08
Efficacy of trastuzumab emtansine (T-DM1) and lapatinib after dual HER2 inhibition with trastuzumab and pertuzumab in patient with metastatic breast cancer: Retrospective data from a French multicenter real-life cohort Moinard-Butot et al. EquipeCTCS 2022-06
Impact of body mass index on overall survival in patients with metastatic breast cancer Saleh et al. EquipePC 2021-02
Clinicopathological characterization of a real-world multicenter cohort of endometrioid ovarian carcinoma: Analysis of the French national ESME-Unicancer database De Nonneville et al. EquipeCTCS 2021-10
Treatment and outcomes in patients with central nervous system metastases from breast cancer in the real-life ESME MBC cohort Pasquier et al. EquipeCTCS Jan 2020
Contemporary outcomes of metastatic breast cancer among 22,000 women from the multicentre ESME cohort 2008-2016 Deluche et al. EquipeCTCS 2020-04
Real-life activity of eribulin mesylate among metastatic breast cancer patients in the multicenter national observational ESME program Jacot et al. EquipeCTCS May 14, 2019
Assessment of the efficacy of successive endocrine therapies in hormone receptor-positive and HER2-negative metastatic breast cancer: a real-life multicentre national study Le Saux et al. EquipePC Sep 2019
Time trends of overall survival among metastatic breast cancer patients in the real-life ESME cohort Gobbini et al. EquipeCTCS Jun 2018
11 Items


Who are we ?

Located in the Parc Euromédecine, the Institut de Recherche en Cancérologie de Montpellier (U1194) is located on the Val d'Aurelle Campus (ICM, Institut régional du Cancer Montpellier/ Val d'Aurelle).

U1194 Research Centre supported by Inserm, the University of Montpellier and the Institut du Cancer de Montpellier (ICM)

More                                                                                                                 Join us

Contact us

Institut de Recherche en Cancérologie de
Montpellier (U1194) - Campus Val d'Aurelle

208 avenue des Apothicaires
34298 Montpellier cedex 5 FRANCE

 

insermUM1ICM

© Institut de Recherche en Cancérologie de Montpellier - 2011 - Tous droits réservés - Mentions légales - Connexion - Conception : ID Alizés